Eubel Brady & Suttman Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,687
| Closed | -$225K | – | 99 |
|
|
2025
Q1 | $225K | Hold |
3,687
| – | – | 0.03% | 87 |
|
|
2024
Q4 | $209K | Buy |
+3,687
| New | +$206K | 0.03% | 87 |
|
|
2022
Q1 | – | Sell |
-3,302
| Closed | -$206K | – | 75 |
|
|
2021
Q4 | $206K | Buy |
+3,302
| New | +$194K | 0.04% | 76 |
|
|
2021
Q3 | – | Sell |
-4,503
| Closed | -$284K | – | 98 |
|
|
2021
Q2 | $284K | Sell |
4,503
-4,503
| -50% | -$294K | 0.02% | 167 |
|
|
2021
Q1 | $568K | Buy |
9,006
+4,903
| +119% | +$305K | 0.06% | 72 |
|
|
2020
Q4 | $255K | Hold |
4,103
| – | – | 0.06% | 70 |
|
|
2020
Q3 | $247K | Buy |
4,103
+236
| +6% | +$14.2K | 0.07% | 64 |
|
|
2020
Q2 | $227K | Hold |
3,867
| – | – | 0.06% | 67 |
|
|
2020
Q1 | $216K | Buy |
+3,867
| New | +$236K | 0.06% | 67 |
|
|
2019
Q1 | – | Sell |
-3,977
| Closed | -$207K | – | 71 |
|
|
2018
Q4 | $207K | Hold |
3,977
| – | – | 0.07% | 64 |
|
|
2018
Q3 | $247K | Hold |
3,977
| – | – | 0.07% | 65 |
|
|
2018
Q2 | $220K | Sell |
3,977
-700
| -15% | -$37.8K | 0.07% | 67 |
|
|
2018
Q1 | $296K | Sell |
4,677
-1,145
| -20% | -$73.7K | 0.09% | 56 |
|
|
2017
Q4 | $357K | Hold |
5,822
| – | – | 0.11% | 61 |
|
|
2017
Q3 | $371K | Hold |
5,822
| – | – | 0.11% | 61 |
|
|
2017
Q2 | $324K | Hold |
5,822
| – | – | 0.1% | 65 |
|
|
2017
Q1 | $317K | Sell |
5,822
-738
| -11% | -$40.5K | 0.1% | 65 |
|
|
2016
Q4 | $383K | Buy |
6,560
+12
| +0.2% | +$656 | 0.12% | 57 |
|
|
2016
Q3 | $353K | Buy |
6,548
+800
| +14% | +$51.4K | 0.11% | 59 |
|
|
2016
Q2 | $423K | Sell |
5,748
-690
| -11% | -$48.8K | 0.14% | 49 |
|
|
2016
Q1 | $411K | Buy |
6,438
+550
| +9% | +$34.7K | 0.14% | 50 |
|
|
2015
Q4 | $405K | Hold |
5,888
| – | – | 0.13% | 50 |
|
|
2015
Q3 | $349K | Sell |
5,888
-1,030
| -15% | -$65.3K | 0.12% | 53 |
|
|
2015
Q2 | $460K | Sell |
6,918
-7
| -0.1% | -$461 | 0.15% | 44 |
|
|
2015
Q1 | $447K | Buy |
6,925
+350
| +5% | +$21.9K | 0.14% | 45 |
|
|
2014
Q4 | $388K | Sell |
6,575
-390
| -6% | -$22K | 0.12% | 51 |
|
|
2014
Q3 | $356K | Hold |
6,965
| – | – | 0.11% | 59 |
|
|
2014
Q2 | $338K | Hold |
6,965
| – | – | 0.1% | 59 |
|
|
2014
Q1 | $362K | Buy |
6,965
+210
| +3% | +$11.2K | 0.1% | 54 |
|
|
2013
Q4 | $359K | Buy |
6,755
+213
| +3% | +$10.8K | 0.1% | 55 |
|
|
2013
Q3 | $303K | Hold |
6,542
| – | – | 0.08% | 66 |
|
|
2013
Q2 | $292K | Buy |
+6,542
| New | +$284K | 0.08% | 68 |
|
Other funds holding BMY
Eubel Brady & Suttman Asset Management's BMY Position: Q2 2025 in Review
Eubel Brady & Suttman Asset Management sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 3,687 shares — an estimated $225K sold.
Eubel Brady & Suttman Asset Management first reported a position in BMY in Q2 2013 and held it in 32 quarters. The position peaked at $568K in Q1 2021. 2,292 funds tracked by Wall St. Rank hold BMY as of Q2 2025.
- Eubel Brady & Suttman Asset Management reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
- Eubel Brady & Suttman Asset Management sold 3,687 Bristol-Myers Squibb shares in Q2 2025, an estimated $225K.
- Eubel Brady & Suttman Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 32 quarters.
- Eubel Brady & Suttman Asset Management's Bristol-Myers Squibb position peaked at $568K in Q1 2021.
- 2,292 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.
Based on Eubel Brady & Suttman Asset Management's 13F filing for Q2 2025, filed 4 Aug 2025.